During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

The Leukemia & Lymphoma Society (LLS) has launched a new docuseries to inform blood cancer patients, caregivers, healthcare ...

I had a fraught relationship with my mother most of my life. Now that she and my brother are both dying of cancer, I'm unsure ...

Lymphoma causes symptoms of organ failure before death. Learn what patients in palliative or hospice care could experience ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Cash runway is robust for now, taking CARGO Therapeutics into 2028 after a planned workforce reduction. Read why I am neutral ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become ...

By studying mutations in malignant T cells that cause lymphoma, they zeroed ... How Gene Activity Modulates the Amount of Immune Cell Production in Mice Jan. 26, 2024 — Researchers describe how ...

Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have ...